Preventing type 2 diabetes;Prévention du diabète de type 2

Sang Thrombose Vaisseaux

Volumn 16, Issue 4, 2004, Pages 193-199

  Virally, Marie Laure ^a   Kevorkian, Jean Philippe ^b   Riveline, Jean Pierre ^a   Varroud Vial, Michel ^a   Requeda, Élisabeth ^a   Charpentier, Guillaume ^a  

^a CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor blockers; Insulinoresistance; Oral antidiabetics agents; Prevention; Type 2 diabetes

Indexed keywords

ACARBOSE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; METFORMIN; NATEGLINIDE; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VALSARTAN;

CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC DIET; DIABETIC OBESITY; DIET THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING; WEIGHT REDUCTION;

EID: 2942748552     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Anaes (Agence nationale d'accréditation et d'évaluation de la santé). Principes de dépistage du diabète de type 2. Février 2003. http://www.anaes.fr.
2. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
3. Guangwei L, Yinghua H, Wenying Y, et al. Effect of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and diabetes study. Diabetes Research and Clinical Practice 2002; 58: 193-200.
4. Diabetes prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformine. (DPPP). N Engl J Med 2002; 346: 393-403.
5. Chiasson JL, Josse RG, Gomis R, et al. The STOP-NIDDM Trial. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290: 486-94.
6. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
7. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. TRIPOD. Diabetes 2002; 51: 2796-803.
8. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of the fat cells. Hypertension 2002; 40: 609-11.
9. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome. IJBCB 2003; 35: 807-25.
10. Engeli S, Gorzelniak K, Kreutz R, et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17: 555-60.
11. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-38.
12. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271-8.
13. Kashiwagi A, Mott D, Bogardus C, et al. The effects of short-term overfeeding on adipocyte metabolism in Pima Indians. Metabolism 1985; 34: 364-70.
14. Paolisso G, tataranni PA, Foley JE, et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-7.
15. Chan P, Wong KL, Liu IM, et al. Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats. J Hypertens 2003; 21: 761-9.
16. Scheen AJ. Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liege 2002; 57: 449-52.
17. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effect on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-33.
18. Paolisso G, Tagliamonte MR, Gambardella A, et al. Losartan mediated improvement in insulin action is mainly due to an increase in no-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997; 11: 307-12.
19. Top C, Cingözbay B, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002; 30: 15-20.
20. Hansson L, Lindholm LH, Niskanen L, et al. The captopril Prevention project (CAPP) randomized trial. Lancet 1999; 353: 611-6.
21. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-5. (HOPE)
22. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-6.
23. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. ALLHAT Officers and Coordinators. JAMA 2002; 288: 2981-7.
24. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
25. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362: 759-66.
26. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.